Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 66.51 | 66.51 | 41.36 | 39.07 | 492.50 | 14.96 | 17.59 | 28.62 |
P/S ratio |
— | 0.00 | 0.00 | 8.85 | 7.22 | 7.71 | 5.37 | 5.05 | 6.98 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 8.13 | 3.78 | 4.16 | 4.72 |
P/Operating CF |
— | 0.00 | 0.00 | 33.22 | 33.74 | 30.28 | 16.38 | 15.40 | 20.08 |
P/B ratio |
— | 0.00 | 0.00 | 1.90 | 1.61 | 1.81 | 1.25 | 1.11 | 1.71 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.90 | 1.61 | 1.81 | 1.26 | 1.11 | 1.89 |
EV/Sales |
— | 0.00 | 0.00 | 10.71 | 9.44 | 10.12 | 8.19 | 7.98 | 10.48 |
EV/EBITDA |
— | 0.00 | 0.00 | 13.94 | 14.67 | 67.75 | 12.75 | 13.76 | 15.65 |
EV/Operating CF |
— | 2.77 | 2.77 | 11.17 | 10.72 | 10.56 | 6.46 | 6.52 | 10.01 |
EV/FCF |
— | 18.65 | 18.65 | (153.96) | (124.27) | 10.66 | 5.77 | 6.56 | 7.09 |
Quick Ratio |
— | — | 1.14 | 6.82 | 13.18 | 1.52 | 3.21 | 0.81 | 1.05 |
Current Ratio |
— | — | 2.50 | 8.76 | 16.81 | 2.19 | 7.90 | 1.44 | 2.40 |
Net Debt/EBITDA |
— | 0.00 | 2.23 | 2.30 | 3.33 | 16.10 | 3.73 | 5.05 | 5.22 |
Debt/Assets |
0.00% | 0.00% | 50.33% | 36.31% | 40.51% | 42.33% | 37.45% | 41.77% | 45.62% |
Debt/Equity |
— | 0.00 | 1.02 | 0.59 | 0.69 | 0.75 | 0.61 | 0.74 | 0.92 |
Asset Turnover |
— | 0.00 | 0.29 | 0.15 | 0.14 | 0.13 | 0.14 | 0.13 | 0.13 |
Operating CF/Net income |
— | 1.17 | 0.71 | 2.09 | 3.26 | 50.06 | 2.63 | 3.22 | 3.23 |
Capex/Depreciation |
— | (5.81) | (46.88) | (62.76) | (50.78) | (0.78) | 0.00 | (0.92) | 0.00 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 29.29% | 12.16% | 6.15% | 0.43% | 11.57% | 8.41% | 7.69% | |
| — | 0.00% | 37.73% | 6.85% | 3.70% | 0.25% | 6.84% | 4.96% | 4.07% | |
ROIC |
— | 0.00% | 13.59% | 7.30% | 5.90% | 1.29% | 5.93% | 4.76% | 5.41% |
Return on Tangible Assets |
— | 0.00% | 20.71% | 6.61% | 3.77% | 0.29% | 7.47% | 5.48% | 4.51% |
Average Days of Receivables |
— | 0.00 | 7.80 | 6.74 | 10.89 | 5.97 | 3.47 | 4.35 | 4.50 |
Research and Development Expense of Revenue |
— | 21.87% | 4.58% | 1.24% | 8.74% | 7.92% | 2.21% | 0.09% | 19.01% |
Selling, General and Administrative Expense of Revenue |
— | 3.45% | 5.70% | 8.56% | 7.99% | 10.16% | 10.61% | 10.46% | 24.11% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.26% | 0.11% | 0.10% | 0.10% | 0.10% | 12.19% |
Graham Net Nets |
— | 0.00 | 0.00 | (0.18) | (0.27) | (0.27) | (0.40) | (0.53) | (0.50) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 23.81 | 6.26 | 30.95 | 27.44 | 26.20 |
Earnings Yield |
— | 1.50% | 1.50% | 2.42% | 2.56% | 0.20% | 6.69% | 5.68% | 3.49% |
Free Cash Flow Yield |
— | 0.00% | 0.00% | (0.79%) | (1.05%) | 12.30% | 26.43% | 24.06% | 21.18% |
Revenue per Share |
— | 0.00 | 4.83 | 5.65 | 5.52 | 5.11 | 5.26 | 5.05 | 5.53 |
Operating CF per Share |
— | 0.00 | 4.44 | 5.42 | 4.86 | 4.90 | 6.68 | 6.18 | 5.79 |
Capex per Share |
— | 0.00 | (4.58) | (5.81) | (5.28) | (0.05) | 0.00 | (0.04) | 0.00 |
Free Cash Flow per Share |
— | 0.00 | (0.14) | (0.39) | (0.42) | 4.85 | 6.68 | 6.14 | 5.79 |
Cash per Share |
— | — | 0.91 | 5.49 | 5.28 | 3.96 | 1.11 | 2.20 | 1.48 |
Shareholders Equity per Share |
— | 0.00 | 16.36 | 26.36 | 24.71 | 21.75 | 22.53 | 23.08 | 22.60 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 16.36 | 26.36 | 24.71 | 21.75 | 22.53 | 23.08 | 22.60 |
Free Cash Flow |
— | 1,348.72 | (54.05) | (147.62) | (173.97) | 2,122.77 | 2,987.80 | 2,750.99 | 2,489.82 |
Working Capital |
— | — | 498.66 | 2,389.01 | 2,706.96 | 1,388.13 | 1,112.82 | 548.52 | 891.88 |
Capital Expenditures |
— | (269.59) | (1,721.29) | (2,182.25) | (2,191.50) | (21.21) | — | (18.00) | — |
Net Current Asset Value |
— | 0.00 | (5,476.38) | (3,427.57) | (4,389.11) | (4,733.18) | (5,023.37) | (6,078.21) | (8,377.75) |
EV/EBIT |
— | 0.00 | 0.00 | 14.25 | 15.11 | 73.72 | 12.93 | 13.97 | 15.98 |
Capex to Sales |
— | 0.15 | 0.95 | 1.03 | 0.96 | 0.01 | 0.00 | 0.01 | 0.00 |
Net Profit Margin |
— | 76.76% | 129.45% | 45.94% | 27.07% | 1.91% | 48.20% | 37.95% | 32.42% |
Price to Operating Income |
— | 10.54 | 10.54 | 11.78 | 11.55 | 56.20 | 8.48 | 8.85 | 10.65 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
— | 0.00% | (71.97%) | (58.14%) | (59.90%) | (61.75%) | (66.41%) | (65.24%) | (71.07%) |
Accounts Receivable Turnover |
— | 0.00 | 46.56 | 54.47 | 42.60 | 42.65 | 79.81 | 91.72 | 84.52 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 38.97 | 38.97 | 53.74 | 52.45 | 29.50 | 24.68 | 28.14 |
Average Payables |
— | — | 10.98 | 10.98 | 8.20 | 6.76 | 11.54 | 14.27 | 16.39 |
Average Assets |
— | 0.00 | 6,224.95 | 14,235.09 | 16,768.08 | 17,164.67 | 16,597.66 | 17,302.28 | 18,921.75 |
Average Common Equity |
— | — | 8,018.63 | 8,018.63 | 10,072.18 | 9,886.96 | 9,804.83 | 10,213.33 | 10,028.65 |
Columns are period end dates